Should desperate volunteers be included in randomised controlled trials?

Journal of Medical Ethics

Volumn 32, Issue 9, 2006, Pages 548-553

  Allmark, P J ^a   Mason, S ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; CLINICAL STUDY; EXPERIMENTAL DESIGN; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; INDIVIDUALITY; INFORMED CONSENT; MEDICAL EXPERT; PATIENT CARE; PATIENT PARTICIPATION; PHYSICIAN; PROFESSIONAL KNOWLEDGE; RANDOMIZATION; RESEARCH ETHICS; VOLUNTEER;

COERCION; ETHICS, RESEARCH; HUMAN EXPERIMENTATION; HUMANS; INFORMED CONSENT; MORAL OBLIGATIONS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RESEARCHER-SUBJECT RELATIONS; UNCERTAINTY;

EID: 33748683775     PISSN: 03066800     EISSN: None     Source Type: Journal    
DOI: 10.1136/jme.2005.014282     Document Type: Article

References (53)

1. Allmark P, Mason S. Improving the quality of consent to randomised controlled trials using continuous consent and clinician training in the consent process. J Med Ethics 2006;32:435-8.
2. Minogue BP, Palmerfernandez G, Udell L, et al. Individual autonomy and the double-blind controlled experiment - the case of desperate volunteers. J Med Philos 1995;20:43-55.
3. Schuklenk U. Drug testing and approval in cases of people with catastrophic illness: ethical issues. Clin Res Regul Affairs 1998;15:145-57.
4. Lilford RJ. Ethics of clinical trials from a Bayesian and decision analytic perspective: whose equipoise is it anyway? BMJ 2003;326:980-1.
5. Schuklenk U. Access to experimental drugs in terminal illness: ethical issues. New York: Pharmaceutica[ Products Press, 1998.
6. Tabrizi SJ, Elliott CL, Weissmann C. Ethical issues in human prion diseases. Br Med Bulletin 2003;66:305-16.
7. Weijer C, Shapiro SH, Glass KC, et al. For and against - clinical equipoise and not the uncertainty principle is the moral underpinning of the randomised controlled trial. BMJ 2000;321:756-8.
8. Rolleston F. Uncertainty about clinical equipoise. Can Med Association J 2001;164:1831.
9. Fried C. Medical experimentation: personal integrity and social policy. Amsterdam: North Holland Publishing, 1974.
10. Miller FG, Brody H. A critique of clinical equipoise - therapeutic misconception in the ethics of clinical trials. Hastings Cent Rep 2003;33:19-28.
11. Weijer C, Miller PB. Therapeutic obligation in clinical research. Hastings Cent Rep 2003;33:3.
12. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 1987;317:141-5.
13. Johnson N, Lilford RJ, Brazier W. At what level of collective equipoise does a clinical trial become ethical. J Med Ethics 1991;17:30-4.
14. Gifford F. Community-equipoise and the ethics of randomized clinical trials. Bioethics 1995;9:127-48.
15. Fries JF, Krishnan E. Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development. Arthritis Res Ther 2004;6:R250-5.
16. Lilford RJ, Jackson J. Equipoise and the ethics of randomization. J R Soc Med 1995;88:552-9.
17. Senn S. The misunderstood placebo. Appl Clin Trials 2001;10:40-6.
18. Gifford F. Freedman's 'clinical equipoise' and 'sliding-scale all-dimensions-considered equipoise'. J Med Philos 2000;25:399-426.
19. Veatch RM. Indifference of subjects: an alternative to equipoise in randomized clinical trials. Soc Philos Policy 2002;19:295-323.
20. Menikoff J. Equipoise: Beyond rehabilitation? Kennedy Inst Ethics J 2003;13:347-51.
21. Dresser R. The ubiquity and utility of the therapeutic misconception. Soc Philos Policy 2002;19:271-94.
22. Glass KC. Clinical equipoise and the therapeutic misconception - Franklin G. Miller and Howard Brody reply. Hastings Cent Rep 2003;33:4-6.
23. Lidz CW, Appelbaum PS, Grisso T, et al. Therapeutic misconception and the appreciation of risks in clinical trials. Soc Sci Med 2004;58:1689-97.
24. Mann H, Djulbegovic B. Clinical equipoise and the therapeutic misconception. Hastings Cent Rep 2003;33:4.
25. Miller FG, Rosenstein DL. The therapeutic orientation to clinical trials. N Engl J Med 2003;348:1383-6.
26. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000;283:2701-11.
27. Brody H, Miller FG. The clinician-investigator: unavoidable but manageable tension. Kennedy Inst Ethics J 2003;13:329-46.
28. Yusuf S. Challenges in the conduct and interpretation of Phase II (pilot) randomized trials. Am Heart J 2000;139:S136-42.
29. Wheatley K, Clayton D. Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization. Cont Clin Trials 2003;24:66-70.
30. Edwards SJ, Lilford RJ, Braunholtz DA, et al. Ethical issues in the design and conduct of randomised controlled trials. Health Technol Assess 1998;2:1-132.
31. Lilford RJ. Equipoise is not synonymous with uncertainty. BMJ 2001;323:574-5.
32. Braunholtz D, Harris J. Quinacrine in possible or probable CJD - if you had suspected CJD would you be indifferent between placebo and quinacrine? BMJ 2002;324:239.
33. Miller PB, Weijer C. Rehabilitating equipoise. Kennedy Inst Ethics J 2003;13:93-118.
34. Food and Drug Administration. Adequate and well-controlled trials. Code of Federal Regulations [revised 1 Apr 2001]. 21 Part 314.126. Washington, DC: US Government Printing Office, 2001.
35. Laughren TP. The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective. Eur Psychiatry 2001;16:418-23.
36. Keating B. Research ethics and the use of the placebo: the state of the debate. MS Med Sci 2004;20:118-25.
37. Michels KB, Rothman KJ. Update on unethical use of placebos in randomised trials. Bioethics 2003;17:188-204.
38. Temple R. Policy developments in regulatory approval. Stat Med 2002;21:2939-48.
39. Eraut M. Developing professional knowledge competence. London: Falmer Press, 1994.
40. Elstein AS. Clinical problem solving and decision psychology: comment on "The epistemology of clinical reasoning". Acad Med 2000; 75:S134-6.
41. Wilson T. Strangers to ourselves: discovering the adaptive unconscious. Cambridge, MA: Belknap, 2002.
42. Myers D. Intuition: its powers and perils. New Haven: Yale University Press, 2002.
43. Paley J. Evidence, empowerment and expertise Norsing Philosophy 2006: in press.
44. Smithells R. Iatrogenic hazards and their effects. Postgrad Med 1995;51(Suppl 2):39-52.
45. Weindling P. Human guinea pigs and the ethics of experimentation: the BMJ's correspondent at the Nuremberg medical trial. BMJ 1996;313:1467-70.
46. Hanauske-Abel HM. Not a slippery slope or sudden subversion: German medicine and national socialism in 1933. BMJ 1996;313:1453-63.
47. Nelson RM, Merz JF. Voluntariness of consent for research - an empirical and conceptual review. Med Care 2002;40:69-80.
48. Bower P, King M, Nazareth I, et al. Patient preferences in randomised controlled trials: conceptual framework and implications for research. Soc Sci Med 2005;61:685-95.
49. Brewin CR, Bradley C. Patient preferences and randomized clinical trials. BMJ 1989;299:313-15.
50. Pedersen AT, Ottesen B. Issues to debate on the Women's Health Initiative (WHI) study. Epidemiology or randomized clinical trials-time out for hormone replacement therapy studies? Hum Reprod 2003;18:2241-4.
51. Pocock SJ. Statistical and ethical issues in monitoring clinical-trials [reprinted from BMJ, 1992;305:235-40].
52. Pocock SJ. Stat Med 1993;12:1459-69.
53. Palmer CR, Rosenberger WF. Ethics and practice: alternative designs for phase III randomized clinical trials. Cont Clin Trials 1999;20:172-86.